Alembic Pharmaceuticals Limited has informed the Exchange about change in Management - Appointment of Chief Financial Officer of the Company
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has appointed Mr. G. Krishnan as its new Chief Financial Officer and Key Managerial Personnel, effective 7th July 2025. Mr. Krishnan brings over 22 years of experience across pharmaceuticals, life sciences, telecom, and the social sector. He is a qualified Chartered Accountant, Company Secretary, and Cost & Management Accountant. Prior to this role, he served as Vice President and CFO of Syngene Scientific Solutions Limited (a Syngene International subsidiary) since May 2020, and earlier held leadership positions at Vodafone and Tata Trusts. His expertise spans business finance, mergers and acquisitions, governance, risk management, and scalable finance systems.
This is a senior leadership change that brings an experienced external finance professional into the company. For shareholders, the appointment signals a focus on strengthening financial governance and strategic planning, though the near-term stock impact is likely to be neutral unless further context on the previous CFO's departure is provided.